CClinicalTrials.gg
CompletedNCT06574295Updated Sep 8, 2026

HTA of NIVATS Based on RWE

An observational study in Lung Cancer, sponsored by Fudan University. Completed at 21 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Fudan University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
876
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This research focuses on a Health Technology Assessment (HTA) of non-intubated video-assisted thoracic surgery (VATS) for lung nodules. Lung cancer, one of the most prevalent malignancies globally, has a high incidence and mortality rate, particularly in China. Traditional treatments like thoracotomy are highly invasive, while conventional thoracoscopic surgery can induce anesthesia-related complications. Non-intubated VATS offers a promising alternative by avoiding intubation and mechanical ventilation, thus reducing complications, anesthesia burden, and recovery time.

The study aims to comprehensively assess the clinical effectiveness, safety, and economic viability of non-intubated VATS for lung cancer treatment through systematic literature reviews, real-world evidence (RWE), and cost-effectiveness analysis. The research will also explore patient preferences using discrete choice experiments (DCE).

By evaluating this technology from a Chinese perspective, the study seeks to provide evidence-based recommendations for the broader adoption of non-intubated VATS in clinical settings.

02

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • Lung cancer
  • Pulmonary nodule
  • VATs
  • NIVATs
03

In context

Lung Neoplasms

7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.

This study's enrollment of 876 is above the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

Fudan University is the lead sponsor of 1,270 studies on the registry; 623 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients aged 18 to 75 years who have been diagnosed with pulmonary nodules or lung cancer and are scheduled for minimally invasive thoracic surgery. These patients will be divided into two groups: an experimental group undergoing non-intubated video-assisted thoracic surgery (VATS) and a control group undergoing intubated VATS. Both groups include individuals who are able to tolerate surgery based on preoperative evaluations, regardless of gender. All participants must provide informed consent and agree to complete the required follow-up assessments.

Inclusion criteria

- Experimental Group (Non-intubated Video-assisted Thoracic Surgery):

  1. Patients diagnosed with pulmonary nodules or lung cancer who are scheduled for minimally invasive surgery (including wedge resection, segmentectomy, or lobectomy).
  2. Aged between 18 and 75 years, regardless of gender.
  3. Preoperative assessment indicates that the patient can tolerate non-intubated video-assisted thoracic surgery.
  4. The patient has signed an informed consent form and voluntarily agrees to participate in the study.

Control Group (Intubated Video-assisted Thoracic Surgery):

  1. Patients diagnosed with pulmonary nodules or lung cancer who are scheduled for minimally invasive surgery (including wedge resection, segmentectomy, or lobectomy).
  2. Aged between 18 and 75 years, regardless of gender.
  3. Preoperative assessment indicates that the patient can tolerate minimally invasive surgery.
  4. The patient has signed an informed consent form and voluntarily agrees to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Patients unable to provide sufficient preoperative and postoperative follow-up data.
  2. Pregnant or breastfeeding women.
  3. Patients with severe cardiopulmonary dysfunction preoperatively, making them unfit for surgery.
  4. Patients who have previously undergone surgery or radiotherapy in the same chest region.
  5. Patients with active infections or other severe comorbidities that may affect surgical outcomes.
  6. Patients with mental illness or cognitive impairment who cannot understand the study content or comply with follow-up requirements.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
876 participants (actual)
Patient registry
No

Groups and cohorts

  • Non-intubated Video-assisted Thoracic Surgery Group

    This group will undergo non-intubated video-assisted thoracic surgery (VATS), a minimally invasive procedure that avoids the use of endotracheal intubation and mechanical ventilation. Instead, patients maintain spontaneous breathing throughout the surgery under regional anesthesia or sedation. The technique is designed to reduce anesthesia-related complications, improve recovery times, and enhance overall patient comfort compared to traditional intubated thoracic surgeries.

  • Intubated Thoracic Surgery Group

    This group will undergo traditional intubated thoracic surgery, where patients are intubated and placed on mechanical ventilation under general anesthesia. This method is commonly used in thoracic surgeries to control the airway and ensure adequate ventilation during the procedure. However, it may be associated with a higher incidence of anesthesia-related complications, such as airway trauma and slower postoperative recovery, compared to non-intubated techniques.

06

What researchers measure

Primary outcomes

  1. Patient-reported Outcomes

    The primary outcome will be assessed using two validated instruments: MD Anderson Symptom Inventory-Lung Cancer (MDASI-LC) and the EQ-5D-5L questionnaire. The Anderson Symptom Inventory will measure symptom severity (e.g., pain, fatigue, nausea, sleep disturbance) and the impact of symptoms on daily functioning, while the EQ-5D will evaluate overall health-related quality of life, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scores will provide insight into patients' recovery and well-being following non-intubated video-assisted thoracic surgery (VATS) compared to traditional intubated thoracic surgery.

    Time frame: Measured within 3 days post-surgery

  2. Postoperative hospitalization time

    The secondary outcome will measure the duration of the postoperative hospital stay. This will be assessed as the number of days from the completion of surgery to the patient's discharge. The goal is to compare the efficiency of recovery between patients undergoing non-intubated video-assisted thoracic surgery (VATS) and those receiving traditional intubated thoracic surgery.

    Time frame: Measured in days from surgery completion to hospital discharge.

07

Study locations

21 sites
  • Anhui Chest Hospital
    Hefei, Anhui 230022, China
  • Chongqing General Hospital
    Chongqing, Chongqing Municipality 401147, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510120, China
  • Guangxi Zhuang Autonomous Region Nanxishan Hospital
    Guilin, Guangxi 541002, China
  • Affiliated Hospital of Hebei University
    Baoding, Hebei 071000, China
  • Cangzhou Central Hospital
    Cangzhou, Hebei 061001, China
  • Anyang Tumor Hospital
    Anyang, Henan 455001, China
  • Wuhan Central Hospital
    Wuhan, Hubei 430014, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • The Second Affiliated Hospital of University of South China
    Hengyang, Hunan 421001, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210008, China
  • Binzhou Medical University Hospital
    Binzhou, Shandong 256603, China
  • The Second Hospital of Shandong University
    Jinan, Shandong 250033, China
  • Affiliated Hospital of Jining Medical University
    Jining, Shandong 272029, China
  • School of Public Health, Fudan University
    Shanghai, Shanghai Municipality 200032, China
  • Deyang People's Hospital
    Deyang, Sichuan 618000, China
  • The First Affiliated Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang 830054, China
  • Anning First People's Hospital
    Anning, Yunnan 650300, China
  • The First People's Hospital of Yunnan Province
    Kunming, Yunnan 650032, China
  • Shaoxing People's Hospital
    Shaoxing, Zhejiang 312000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06574295
Lead sponsor
Fudan University
Responsible party
Yingyao Chen (Professor, Fudan University) — Principal investigator
First posted
Aug 27, 2024
Start date
Aug 20, 2024
Primary completion
Jan 24, 2025
Completion
Jan 30, 2025
Last update
Sep 8, 2026

Study contacts

Yingyao Chen, PhD
study chair · School of Public Health,Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion